Reconsidering Drugs Funded Via The Cancer Drugs Fund in England: What’s New This Time?
نویسندگان
چکیده
منابع مشابه
NEW DRUGS DRUG NEWS NEW DRUGS Cervical Cancer Vaccine
NEW DRUGS Cervical Cancer Vaccine The Food and Drug Administration (FDA) has approved Gardasil (Merck), the first vaccine developed to prevent cervical cancer, precancerous genital lesions, and genital warts caused by human papilloma virus (HPV) types 6, 11, 16, and 18 for females nine to 26 years of age. This agent was evaluated and approved in six months under the FDA’s priority review proces...
متن کاملNew drugs in prostate cancer
The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other...
متن کاملDo patient access schemes for high-cost cancer drugs deliver value to society?—lessons from the NHS Cancer Drugs Fund
Background The NHS Cancer Drugs Fund (CDF) was established in 2010 to reduce delays and improve access to cancer drugs, including those that had been previously appraised but not approved by NICE (National Institute for Health and Care Excellence). After 1.3 billion GBP expenditure, a UK parliamentary review in 2016 rationalized the CDF back into NICE. Methods This paper analyses the potentia...
متن کاملNew drugs for breast cancer.
Recently there have been significant advances in rational drug design for the treatment of breast cancer, especially in the area of targeted drug therapy. These include drugs which target the HER2 receptor and angiogenesis and the novel class of drug the PARP inhibitors. Some of these agents, for example, trastuzumab used in the treatment of HER2 positive breast cancer are already established a...
متن کاملReanalysis of cancer drugs: old drugs, new tricks.
George F. Vande Woude, Gary J. Kelloff, Raymond W. Ruddon, Han-Mo Koo, Caroline C. Sigman, J. Carl Barrett, Robert W. Day, Adam P. Dicker, Robert S. Kerbel, David R. Parkinson, and William J. Slichenmyer Van Andel Research Institute, Grand Rapids, Michigan; Division of Cancer Treatment and Diagnosis and Center for Cancer Research, National Cancer Institute, Bethesda, Maryland; Johnson & Johnson...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2016
ISSN: 1098-3015
DOI: 10.1016/j.jval.2016.09.2370